GRCL צמיחת רווחי EPS רבעונית Gracell Biotechnologies Inc.
Gracell Biotechnologies (GRCL) is recognized as a leader in CAR-T cell engineering via its FasTCAR platform for the treatment of hematological malignancies. The quarterly EPS growth rate reflects current dynamics, where 69.40 characterizes this valuation parameter. While the company is scaling tests through contract manufacturers, high costs and therapy safety risks may delay the business from reaching break-even.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_GRCL_-_Gracell-Biotechnologies_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "gracellbio.com (GRCL): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 03.03.2024 | 👁️GURU.Markets👁️")
Gracell (GRCL) - פילוחי מדדים ודוחות פיננסיים
The recognition of Gracell Biotechnologies (GRCL) as a cell therapy leader following its acquisition by a pharma behemoth shifts the valuation of its assets into a realm of high market confidence. The quarterly earnings per share history, featuring the value 69.40, daily bridges the information gap between reports by measuring net income dynamics to identify overpayment risks during rallies or recovery potential during downturns.
